UBS Group’s Merck MRK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $54.6M | Sell |
454,300
-154,000
| -25% | -$17.8M | 0.01% | 1557 |
|
|
2025
Q4 | $64M | Sell |
608,300
-394,500
| -39% | -$37M | 0.01% | 1383 |
|
|
2025
Q3 | $84.2M | Buy |
1,002,800
+158,900
| +19% | +$13.1M | 0.01% | 1158 |
|
|
2025
Q2 | $66.8M | Sell |
843,900
-245,500
| -23% | -$19.5M | 0.01% | 1261 |
|
|
2025
Q1 | $97.8M | Buy |
1,089,400
+161,800
| +17% | +$15.1M | 0.02% | 947 |
|
|
2024
Q4 | $92.3M | Sell |
927,600
-327,000
| -26% | -$33.7M | 0.02% | 973 |
|
|
2024
Q3 | $142M | Buy |
1,254,600
+404,600
| +48% | +$48.1M | 0.03% | 562 |
|
|
2024
Q2 | $105M | Sell |
850,000
-166,000
| -16% | -$21.4M | 0.03% | 627 |
|
|
2024
Q1 | $134M | Sell |
1,016,000
-240,014
| -19% | -$29.6M | 0.03% | 512 |
|
|
2023
Q4 | $137M | Buy |
1,256,014
+745,314
| +146% | +$77.4M | 0.04% | 449 |
|
|
2023
Q3 | $52.6M | Sell |
510,700
-169,900
| -25% | -$18.3M | 0.02% | 813 |
|
|
2023
Q2 | $78.5M | Sell |
680,600
-422,200
| -38% | -$47.9M | 0.03% | 597 |
|
|
2023
Q1 | $117M | Sell |
1,102,800
-348,600
| -24% | -$37.6M | 0.04% | 402 |
|
|
2022
Q4 | $161M | Buy |
1,451,400
+352,800
| +32% | +$36.1M | 0.06% | 333 |
|
|
2022
Q3 | $94.6M | Buy |
1,098,600
+284,900
| +35% | +$25.4M | 0.04% | 446 |
|
|
2022
Q2 | $74.2M | Buy |
813,700
+23,754
| +3% | +$2.11M | 0.03% | 549 |
|
|
2022
Q1 | $64.8M | Buy |
789,946
+222,344
| +39% | +$17.5M | 0.02% | 710 |
|
|
2021
Q4 | $43.5M | Buy |
567,602
+464,577
| +451% | +$37M | 0.01% | 1046 |
|
|
2021
Q3 | $7.74M | Buy |
103,025
+55,402
| +116% | +$4.21M | ﹤0.01% | 2247 |
|
|
2021
Q2 | $3.7M | Sell |
47,623
-504,788
| -91% | -$37.5M | ﹤0.01% | 2985 |
|
|
2021
Q1 | $40.6M | Sell |
552,411
-20,740
| -4% | -$1.53M | 0.01% | 973 |
|
|
2020
Q4 | $44.7M | Sell |
573,151
-3,249
| -0.6% | -$248K | 0.02% | 840 |
|
|
2020
Q3 | $45.6M | Sell |
576,400
-89,290
| -13% | -$6.99M | 0.02% | 693 |
|
|
2020
Q2 | $49.1M | Buy |
665,690
+32,174
| +5% | +$2.42M | 0.02% | 620 |
|
|
2020
Q1 | $46.5M | Buy |
633,516
+108,049
| +21% | +$8.49M | 0.02% | 574 |
|
|
2019
Q4 | $45.6M | Buy |
525,467
+28,401
| +6% | +$2.33M | 0.02% | 831 |
|
|
2019
Q3 | $39.9M | Buy |
497,066
+286,837
| +136% | +$23M | 0.02% | 808 |
|
|
2019
Q2 | $16.8M | Sell |
210,229
-503,354
| -71% | -$38.5M | 0.01% | 1334 |
|
|
2019
Q1 | $56.6M | Buy |
713,583
+208,237
| +41% | +$15.6M | 0.02% | 575 |
|
|
2018
Q4 | $36.8M | Sell |
505,346
-6,183
| -1% | -$436K | 0.02% | 750 |
|
|
2018
Q3 | $34.6M | Sell |
511,529
-209,495
| -29% | -$13.3M | 0.01% | 859 |
|
|
2018
Q2 | $41.8M | Sell |
721,024
-105,324
| -13% | -$5.94M | 0.02% | 738 |
|
|
2018
Q1 | $42.9M | Sell |
826,348
-183,190
| -18% | -$9.89M | 0.02% | 704 |
|
|
2017
Q4 | $54.2M | Buy |
1,009,538
+503,354
| +99% | +$27.9M | 0.02% | 636 |
|
|
2017
Q3 | $30.9M | Buy |
506,184
+1,153
| +0.2% | +$69.9K | 0.01% | 853 |
|
|
2017
Q2 | $30.9M | Sell |
505,031
-267,240
| -35% | -$16.3M | 0.02% | 803 |
|
|
2017
Q1 | $46.8M | Buy |
772,271
+167,470
| +28% | +$10.2M | 0.03% | 575 |
|
|
2016
Q4 | $34M | Buy |
604,801
+66,024
| +12% | +$3.86M | 0.02% | 722 |
|
|
2016
Q3 | $32.1M | Sell |
538,777
-184,867
| -26% | -$10.8M | 0.02% | 701 |
|
|
2016
Q2 | $39.8M | Buy |
723,644
+397,087
| +122% | +$21.1M | 0.03% | 591 |
|
|
2016
Q1 | $16.5M | Sell |
326,557
-597,465
| -65% | -$29.3M | 0.01% | 1009 |
|
|
2015
Q4 | $46.6M | Sell |
924,022
-84,049
| -8% | -$4.24M | 0.03% | 529 |
|
|
2015
Q3 | $47.5M | Buy |
1,008,071
+262,419
| +35% | +$13.9M | 0.03% | 489 |
|
|
2015
Q2 | $40.5M | Buy |
745,652
+290,506
| +64% | +$16.3M | 0.03% | 606 |
|
|
2015
Q1 | $25M | Sell |
455,146
-284,952
| -39% | -$16.1M | 0.02% | 829 |
|
|
2014
Q4 | $40.1M | Buy |
+740,098
| New | +$41.2M | 0.03% | 630 |
|
Other funds holding MRK
VCM
VPM
UBS Group's MRK Position: Q1 2026 in Review
UBS Group reduced its Merck (MRK) stake by 27% in Q1 2026, selling an estimated $605M and leaving 13,933,630 shares worth $1.68B. The position accounts for 0.25% of the portfolio, ranked #65.
UBS Group first reported a position in MRK in Q4 2014 and has held it in 46 quarters since. The position peaked at $2.02B in Q4 2025. 3,778 funds tracked by Wall St. Rank hold MRK as of Q1 2026.
- UBS Group held 13,933,630 shares of Merck worth $1.68B as of Q1 2026.
- UBS Group sold 5,244,642 Merck shares in Q1 2026, an estimated $605M.
- Merck made up 0.25% of UBS Group's portfolio in Q1 2026, its #65 holding.
- UBS Group first reported a position in Merck in Q4 2014 and has held it in 46 quarters since.
- UBS Group's Merck position peaked at $2.02B in Q4 2025.
- 3,778 funds tracked by Wall St. Rank held Merck as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.